SCHEMBL24251148

SCHEMBL24251148

Cc1ccc(NC(=O)c2ccc(N3CCN(C(=O)OCOCc4ccccc4)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 14/20 0.65
BCR P11274 13/20 0.65
PDGFRA P16234 13/20 0.65
PDGFRB P09619 5/20 0.65
EGFR P00533 2/20 0.65
PRKCA P17252 1/20 0.65
KIT P10721 10/20 0.62
PLK4 O00444 1/20 0.62
DDX3X O00571 1/20 0.62
GAK O14976 1/20 0.62
SLC22A2 O15244 1/20 0.62
MAPK13 O15264 1/20 0.62
CA12 O43570 1/20 0.62
SLC22A3 O75751 1/20 0.62
ABCB11 O95342 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
LMNA P02545 1/20 0.62
ALB P02768 1/20 0.62
RAF1 P04049 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551707 1.00 ABL1 (0.65) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL24251061 0.96 ABL1 (0.59) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL29551438 0.96 ABL1 (0.59) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL29551037 0.92 ABL1 (0.69) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL24251159 0.92 ABL1 (0.69) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL24250947 0.90 ABL1 (0.63) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL29551496 0.90 ABL1 (0.63) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL24250967 0.88 PDGFRA (0.62) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL29551797 0.88 PDGFRA (0.62) ABL1BCRPDGFRAPDGFRBEGFR
SCHEMBL24251140 0.87 ABL1 (0.61) ABL1BCRPDGFRAPDGFRBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127065-A Compounds for the treatment of neurodegenerative diseases and cancer 鸿仪有限责任公司 2022-03-01 CN claimed
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 ABL1 695/4885BCR 1219/4885PDGFRA 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.